Just Biotherapeutics

Acquired
Seattle

Facts

HQ
Seattle
Sectors
Biotechnology, Biomanufacturing, Therapeutics
Founded
2014
Status
Acquired
Stage
Acquired

Is this your organization? Claim it

Archive: Just Biotherapeutics: a startup case study (Fundamentals for Startups)

(https://comotion.uw.edu/) Dean Pettit, former co-founder and chief scientific officer, UW Bioengineering Lecturer and UW PhD graduate coaches bioengineering students on how to work with the latest industry-specific tools they’ll need to navigate career pathways, while keeping an eye on the marketplace. He spoke about an AI/ML application for therapeutic discovery in the biotech industry, and strategies that can empower startups working at the intersection of global health and product development.

Just–Evotec Biologics opens 130,000 sq ft Redmond J.POD to manufacture COVID‑19 antibody therapeutics for U.S. Defense

Just–Evotec Biologics opened a 130,000 sq ft J.POD drug manufacturing facility in Redmond, Washington that uses continuous, autonomous bioprocessing to design, develop and produce antibody therapeutics more efficiently and at lower cost. The plant will manufacture antibodies for the U.S. Department of Defense to potentially treat COVID-19 and supports both small- and large-scale production for biotech customers globally.

Evotec to Acquire Seattle’s Just Biotherapeutics for Up to $90M; Gates Foundation-Backed Startup Joins German Drug-Discovery Firm

Seattle-based Just Biotherapeutics, backed by investors including the Bill & Melinda Gates Foundation, agreed to be acquired by German drug-discovery firm Evotec for up to $90 million, with part of the price contingent on milestones. Just’s CEO James Thomas will lead U.S. operations at Evotec as executive vice president and global head of biotherapeutics, and the deal aims to add biologics capabilities to Evotec’s pipeline.

See all 6 stories, episodes and videos about Just Biotherapeutics.